GSK’s (GSK) Buy Rating Reaffirmed at Deutsche Bank Aktiengesellschaft
GSK (LON:GSK – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Deutsche Bank Aktiengesellschaft in a report released on Tuesday, Digital Look reports. They presently have a GBX 1,950 ($24.73) target price on the stock. Deutsche Bank Aktiengesellschaft’s target price suggests a potential upside of 16.71% from the company’s current […]
More Stories
Rocket Pharmaceuticals (NASDAQ:RCKT) Earns “Buy” Rating from Chardan Capital
Chardan Capital reaffirmed their buy rating on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a report published on...
Calumet Specialty Products Partners (NASDAQ:CLMT) Rating Increased to Sell at StockNews.com
StockNews.com upgraded shares of Calumet Specialty Products Partners (NASDAQ:CLMT – Free Report) to a sell rating in a research report...
Pure Cycle (NASDAQ:PCYO) Upgraded at StockNews.com
StockNews.com upgraded shares of Pure Cycle (NASDAQ:PCYO – Free Report) from a sell rating to a buy rating in a...
HP Inc. (NYSE:HPQ) Shares Acquired by Swiss National Bank
Swiss National Bank lifted its holdings in shares of HP Inc. (NYSE:HPQ – Free Report) by 0.3% in the 3rd...
Swiss National Bank Grows Holdings in Old Dominion Freight Line, Inc. (NASDAQ:ODFL)
Swiss National Bank grew its holdings in Old Dominion Freight Line, Inc. (NASDAQ:ODFL – Free Report) by 0.1% during the...
Swiss National Bank Buys 25,000 Shares of PG&E Co. (NYSE:PCG)
Swiss National Bank lifted its stake in PG&E Co. (NYSE:PCG – Free Report) by 0.4% during the 3rd quarter, according...